The EMPA-KIDNEY trial was a study that evaluated the effects of empagliflozin, a medication, on patients with chronic kidney disease who are at risk for disease progression. The study enrolled 6609 patients who were randomly assigned to receive empagliflozin or matching placebo. The study found that empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo over a median of 2.0 years of follow-up. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group, but there were no significant differences in the composite outcome of hospitalization for heart failure or death from cardiovascular causes or death from any cause. The rates of serious adverse events were similar in the two groups.
https://www.nejm.org/doi/full/10.1056/NEJMoa2204233?query=featured_cardiology
Leave a Reply